Takeda Partners with Innovent Biologics to Boost Oncology Pipeline with Advanced Solid Tumor Therapies

Shots:Takeda & Innovent Biologics have entered into a global Partnership (Excluding Greater China) to develop & Commercialize IBI363 & IBI343; Takeda also Gains exclusive Option to license global rights for IBI3001 outside of Greater ChinaAs per the deal, Takeda will pay Innovent $1.2B upfront, including a $100M equity investment, funded from cash on…

ByDipanshu Dixit3 days ago

NEWS

Fangzhou Joins Forces with Innovent Biologics for AI-Driven Metabolic & Weight Management Solutions

Shots:Fangzhou has partnered with Innovent Biologics to combine digital health services with novel therapies in metabolic diseases & weight managementCollaboration will integrate Fangzhou’s AI-driven H2H healthcare ecosystem with Innovent’s pipeline, incl. Mazdutide, & leverage Fangzhou’s XS Core AI large language model powering 5 AI tools: AI Medication Finder, AI Health Manager, AI Doctor…

ByRidhi RastogiSeptember 10, 2025

NEWS

HUTCHMED and Innovent Biologics Report NMPA’s NDA Acceptance of Fruquintinib + Sintilimab for Renal Cell Carcinoma

Shots:China’s NMPA has accepted NDA of fruquintinib + sintilimab for the treatment of pts with locally advanced or metastatic renal cell carcinoma who have progressed on one tyrosine kinase inhibitor therapyNDA is backed by the P-II/III (FRUSICA-2) trial assessing fruquintinib + sintilimab vs axitinib/everolimus monotx. for 2L treatment of renal cell carcinoma pts…

ByRidhi RastogiJune 5, 2025

NEWS

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

Shots:Innovent & Roche have entered into a collaboration & exclusive license agreement for developing IBI3009 to treat advanced SCLC As per the terms, Roche secures exclusive worldwide rights to develop, manufacture & commercialize IBI3009 plus will lead full development after early-stage studies, conducted jointly. Innovent will get $80M upfront, up to $1B development…

ByRidhi RastogiJanuary 2, 2025

INSIGHTS+

New Drug Designations – November 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…

BySenior EditorDecember 27, 2023

INSIGHTS+

Insights+ Key Biosimilars Events of January 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the USOur team at PharmaShots has summarized key…

BySenior EditorFebruary 14, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space…

BySenior EditorSeptember 9, 2019

Takeda Partners with Innovent Biologics to Boost Oncology Pipeline with Advanced Solid Tumor Therapies

Fangzhou Joins Forces with Innovent Biologics for AI-Driven Metabolic & Weight Management Solutions

HUTCHMED and Innovent Biologics Report NMPA’s NDA Acceptance of Fruquintinib + Sintilimab for Renal Cell Carcinoma

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

New Drug Designations – November 2023

Insights+ Key Biosimilars Events of January 2020

Insights+ Key Biosimilars Events of August 2019

Contact US

OUR INFORMATION

FOLLOW US